Cargando…

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bancroft, Elizabeth K., Saya, Sibel, Page, Elizabeth C., Myhill, Kathryn, Thomas, Sarah, Pope, Jennifer, Chamberlain, Anthony, Hart, Rachel, Glover, Wayne, Cook, Jackie, Rosario, Derek J., Helfand, Brian T., Hutten Selkirk, Christina, Davidson, Rosemarie, Longmuir, Mark, Eccles, Diana M., Gadea, Neus, Brewer, Carole, Barwell, Julian, Salinas, Monica, Greenhalgh, Lynn, Tischkowitz, Marc, Henderson, Alex, Evans, David Gareth, Buys, Saundra S., Eeles, Rosalind A., Aaronson, Neil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378691/
https://www.ncbi.nlm.nih.gov/pubmed/29802810
http://dx.doi.org/10.1111/bju.14412
_version_ 1783395968098500608
author Bancroft, Elizabeth K.
Saya, Sibel
Page, Elizabeth C.
Myhill, Kathryn
Thomas, Sarah
Pope, Jennifer
Chamberlain, Anthony
Hart, Rachel
Glover, Wayne
Cook, Jackie
Rosario, Derek J.
Helfand, Brian T.
Hutten Selkirk, Christina
Davidson, Rosemarie
Longmuir, Mark
Eccles, Diana M.
Gadea, Neus
Brewer, Carole
Barwell, Julian
Salinas, Monica
Greenhalgh, Lynn
Tischkowitz, Marc
Henderson, Alex
Evans, David Gareth
Buys, Saundra S.
Eeles, Rosalind A.
Aaronson, Neil K.
author_facet Bancroft, Elizabeth K.
Saya, Sibel
Page, Elizabeth C.
Myhill, Kathryn
Thomas, Sarah
Pope, Jennifer
Chamberlain, Anthony
Hart, Rachel
Glover, Wayne
Cook, Jackie
Rosario, Derek J.
Helfand, Brian T.
Hutten Selkirk, Christina
Davidson, Rosemarie
Longmuir, Mark
Eccles, Diana M.
Gadea, Neus
Brewer, Carole
Barwell, Julian
Salinas, Monica
Greenhalgh, Lynn
Tischkowitz, Marc
Henderson, Alex
Evans, David Gareth
Buys, Saundra S.
Eeles, Rosalind A.
Aaronson, Neil K.
author_sort Bancroft, Elizabeth K.
collection PubMed
description OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36‐item short‐form health survey (SF‐36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale‐Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants’ perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF‐36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer‐specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.
format Online
Article
Text
id pubmed-6378691
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63786912019-02-28 Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations Bancroft, Elizabeth K. Saya, Sibel Page, Elizabeth C. Myhill, Kathryn Thomas, Sarah Pope, Jennifer Chamberlain, Anthony Hart, Rachel Glover, Wayne Cook, Jackie Rosario, Derek J. Helfand, Brian T. Hutten Selkirk, Christina Davidson, Rosemarie Longmuir, Mark Eccles, Diana M. Gadea, Neus Brewer, Carole Barwell, Julian Salinas, Monica Greenhalgh, Lynn Tischkowitz, Marc Henderson, Alex Evans, David Gareth Buys, Saundra S. Eeles, Rosalind A. Aaronson, Neil K. BJU Int Urological Oncology OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36‐item short‐form health survey (SF‐36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale‐Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants’ perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF‐36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer‐specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening. John Wiley and Sons Inc. 2018-06-22 2019-02 /pmc/articles/PMC6378691/ /pubmed/29802810 http://dx.doi.org/10.1111/bju.14412 Text en © 2018 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Urological Oncology
Bancroft, Elizabeth K.
Saya, Sibel
Page, Elizabeth C.
Myhill, Kathryn
Thomas, Sarah
Pope, Jennifer
Chamberlain, Anthony
Hart, Rachel
Glover, Wayne
Cook, Jackie
Rosario, Derek J.
Helfand, Brian T.
Hutten Selkirk, Christina
Davidson, Rosemarie
Longmuir, Mark
Eccles, Diana M.
Gadea, Neus
Brewer, Carole
Barwell, Julian
Salinas, Monica
Greenhalgh, Lynn
Tischkowitz, Marc
Henderson, Alex
Evans, David Gareth
Buys, Saundra S.
Eeles, Rosalind A.
Aaronson, Neil K.
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title_full Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title_fullStr Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title_full_unstemmed Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title_short Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
title_sort psychosocial impact of undergoing prostate cancer screening for men with brca1 or brca2 mutations
topic Urological Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378691/
https://www.ncbi.nlm.nih.gov/pubmed/29802810
http://dx.doi.org/10.1111/bju.14412
work_keys_str_mv AT bancroftelizabethk psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT sayasibel psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT pageelizabethc psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT myhillkathryn psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT thomassarah psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT popejennifer psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT chamberlainanthony psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT hartrachel psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT gloverwayne psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT cookjackie psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT rosarioderekj psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT helfandbriant psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT huttenselkirkchristina psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT davidsonrosemarie psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT longmuirmark psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT ecclesdianam psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT gadeaneus psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT brewercarole psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT barwelljulian psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT salinasmonica psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT greenhalghlynn psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT tischkowitzmarc psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT hendersonalex psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT evansdavidgareth psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT buyssaundras psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT eelesrosalinda psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations
AT aaronsonneilk psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations